Charles W. Drescher
M.D., University of Michigan, Medicine, 1982.
Dr. Drescher is a partner and gynecologic surgeon at Pacific Gynecology Specialists located on the Swedish Medical Center campus in Seattle, Washington. His primary academic appointments are with the University of Washington as a Clinical Professor in the Department of Obstetrics and Gynecology with a joint appointment to the Translational and Outcomes Research Group in the Molecular Diagnostics Program at the Fred Hutchinson Center as an Associate Member. Dr. Drescher earned his Medical Degree in Medicine at the University of Michigan in Ann Arbor, where he also completed a residency in Obstetrics and Gynecology and a fellowship in Gynecologic Oncology.
Dr. Drescher is a co-Principal Investigator of a Specialized Program of Research Excellence (SPORE) in Ovarian Cancer grant funded by the National Cancer Institute where he oversees the recruitment and enrollment of ovarian cancer patients into a surgical (tissue) donation program. Dr. Drescher has extensive experience in collecting and processing tissues and blood specimens from patients, which are banked in the SPORE's Specimen Repository for use in research studies. In addition, he co-leads a SPORE project focused on molecular targets for ovarian cancer prognosis and therapy. As an expert in gynecological oncology, Dr. Drescher is actively involved in many ovarian cancer research organizations including on the Cancer Prevention committee of the Gynecological Oncology Group (GOG) and the Executive Committees of the Puget Sound Oncology Consortium and Pacific Ovarian Cancer Research Consortium. He is the former Medical Director of the Marsha Rivkin Center for Ovarian Cancer Research.
American Medical Association
Gynecologic Cancer Foundation
King County Medical Society
Seattle Gynecological Society
Society of Gynecologic Oncologists
Washington State Medical Association
1996-2005, Medical Director, Marsha Rivkin Center for Ovarian Cancer Research
1991-1998, Clinical Assistant Professor, University of Washington, School of Medicine, Obstetrics and Gynecology
1987-1989, Instructor, University of Michigan, Gynecological Oncology, Medical Center
1986-1987, Guest Lecturer and Surgeon, Komfo Anokye Teaching Hospital
Longitudinal Screening Algorithm That Incorporates Change Over Time in CA125 Levels Identifies Ovarian Cancer Earlier Than a Single-Threshold Rule.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 31(3):387-92.. 2013.
Dangerous Combinations: Ingestible CAM Supplement Use During Chemotherapy in Patients with Ovarian Cancer.. Journal of alternative and complementary medicine (New York, N.Y.).. 2013.
Interpretation of Single and Serial Measures of HE4 and CA125 in Asymptomatic Women at High Risk for Ovarian Cancer.. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. 21(11):2087-94.. 2012.
Involvement in decision-making about treatment and ovarian cancer survivor quality of life.. Gynecologic oncology. 124(3):465-470.. 2012.
Impact of screening test performance and cost on mortality reduction and cost-effectiveness of multimodal ovarian cancer screening.. Cancer prevention research (Philadelphia, Pa.).. 2012.
An integrative genomic approach identifies p73 and p63 as activators of miR-200 microRNA family transcription.. Nucleic acids research. 40(2):499-510.. 2012.
ESRRA-C11orf20 is a recurrent gene fusion in serous ovarian carcinoma.. PLoS biology. 9(9):e1001156.. 2011.
Large prospective study of ovarian cancer screening in high-risk women: CA125 cut-point defined by menopausal status.. Cancer prevention research (Philadelphia, Pa.). 4(9):1401-8.. 2011.
Potential Role of HE4 in Multimodal Screening for Epithelial Ovarian Cancer.. Journal of the National Cancer Institute. 103(21):1630-4.. 2011.
Early diagnosis of ovarian carcinoma: is a solution in sight? Radiology. 259(2):329-45.. 2011.
Desmoglein 2 is a receptor for adenovirus serotypes 3, 7, 11 and 14.. Nature medicine. 17(1):96-104.. 2011.
Use of a Symptom Index, CA125, and HE4 to predict ovarian cancer.. Gynecologic oncology. 116(3):378-83.. 2010.
Assessing lead time of selected ovarian cancer biomarkers: a nested case-control study.. Journal of the National Cancer Institute. 102(1):26-38.. 2010.
Regulation of miR-200 family microRNAs and ZEB transcription factors in ovarian cancer: evidence supporting a mesothelial-to-epithelial transition.. Gynecologic oncology. 116(1):117-25.. 2010.
Activation of the MEK-S6 pathway in high-grade ovarian cancers.. Applied immunohistochemistry & molecular morphology : AIMM / official publication of the Society for Applied Immunohistochemistry. 18(6):499-508.. 2010.
DNA methylation profiles of ovarian epithelial carcinoma tumors and cell lines.. PloS one. 5(2):e9359.. 2010.
Influence of ovarian cancer risk status on the diagnostic performance of the serum biomarkers mesothelin, HE4, and CA125.. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. 18(5):1365-72.. 2009.
Epithelial phenotype confers resistance of ovarian cancer cells to oncolytic adenoviruses.. Cancer research. 69(12):5115-25.. 2009.
Quality assessment and data analysis for microRNA expression arrays.. Nucleic acids research. 37(2):e17.. 2009.
Quantitative proteomics analysis integrated with microarray data reveals that extracellular matrix proteins, catenins, and p53 binding protein 1 are important for chemotherapy response in ovarian cancers.. Omics : a journal of integrative biology. 13(4):345-54.. 2009.
The temporal stability of the Symptom Index among women at high-risk for ovarian cancer.. Gynecologic oncology. 114(2):225-30.. 2009.